The main objective of WP4 is to assess the validity and usefulness of omics signatures identified and validated in WPs 1, 2 and 3 for improved identification and risk stratification of patients with EHBP and stratification of patients with PHT.
The specific objectives of the WP are:
- To compare the diagnostic accuracy of omics-based signatures for identifying patients with EHBP compared with standard procedures.
- To determine the prognostic value of the omics signatures by assessing their relationship with outcome measures after one year follow-up, including BP, BP related target organ damage (TOD) and QoL.
- To assess the potential usefulness of the omics signatures for stratification of patients with PHT.
- To relate the use of omics signatures to the social impact of hypertension, including QoL, degree of psychosocial burden, patients’ lives and economic effects.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633983
